ClinicalTrials.gg
RecruitingNCT07689357Updated Jul 8, 2026

Cervical Ripening Balloon, 3 Hours vs 12 Hours Placement

An interventional study of Cook Cervical Ripening Balloon 3 hours and Cook Cervical Ripening Balloon 12 hours in Labor Induction and Cervical Ripening and Induction of Labor, sponsored by Rambam Health Care Campus. Recruiting at 1 site in Israel. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-07-08.

Sponsored by Rambam Health Care Campus · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
164
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

The goal of this clinical trial is to learn if a shorter duration of cervical ripening balloon (CRB) placement can reduce the time to delivery in pregnant women undergoing induction of labor.

The main questions it aims to answer are:

Does placing the cervical ripening balloon for 3 hours or less result in a shorter interval from insertion to delivery compared to the standard 12-hour placement?

Does a shorter 3-hour balloon placement lead to better pregnancy outcomes, fewer complications, and lower maternal discomfort?

Researchers will compare a group of participants who have the balloon removed after 3 hours to a control group who have the balloon removed after 12 hours to see if the shorter duration decreases the overall time to delivery.

Participants will:

Sign an informed consent and be randomized into one of the two groups (3 hours vs. 12 hours).

Undergo the standard procedure of a double-lumen Cook cervical ripening balloon insertion.

Have the balloon removed after approximately 3 hours or 12 hours depending on their assigned group.

Proceed with amniotomy or Pitocin use at the discretion of the labor and delivery physician.

Complete a Birth Satisfaction Scale questionnaire and have their maternal and neonatal health outcomes tracked from the hospital's database.

02

Conditions studied

  • Labor Induction
  • Cervical Ripening and Induction of Labor
03

In context

Lead sponsor

Rambam Health Care Campus is the lead sponsor of 466 studies on the registry; 34 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Nulliparous or multiparous pregnant women.
  • Gestational age between 37 0/7 and 41 6/7 weeks of gestation.
  • Maternal age between 18 and 45 years.
  • Participant has provided signed .

Exclusion criteria

Exclusion Criteria:

  • Presence of any for vaginal delivery.
  • Multifetal gestation.
  • Rupture of membranes prior to balloon insertion.
  • Favorable cervix, defined as a Bishop score greater than 6.
  • Cervical dilation greater than 2 cm.
  • Previous cesarean delivery or any other prior major uterine surgery.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
164 participants (estimated)

Study arms

  • Experimental
    3 hours balloon group

    Double-balloon cervical ripening catheter inserted and left in place for 3 hours before removal

    Device: Cook Cervical Ripening Balloon 3 hours

  • Active comparator
    12 hours balloon group

    Double-balloon cervical ripening catheter inserted and left in place for 12 hours before removal

    Device: Cook Cervical Ripening Balloon 12 hours

Interventions

  • DeviceCook Cervical Ripening Balloon 3 hours

    Use of a transcervical balloon catheter for pre-induction cervical ripening. The catheter is inserted through the cervix, the balloon(s) inflated with sterile saline. The device remains in place for 3 hours.

  • DeviceCook Cervical Ripening Balloon 12 hours

    Use of a transcervical balloon catheter for pre-induction cervical ripening. The catheter is inserted through the cervix, the balloon(s) inflated with sterile saline. The device remains in place for 12 hours.

06

What researchers measure

Primary outcomes

  1. Insertion-to-Delivery Time Interval

    The time interval (in hours) from the successful insertion of the cervical ripening balloon to the time of fetal delivery (whether vaginal or cesarean section).

    Time frame: From the time of balloon insertion up to delivery (approximately 48 hours).

Secondary outcomes

  1. Mode of Delivery

    The rates of successful vaginal deliveries, instrumental deliveries (vacuum), and cesarean deliveries between the two groups.

    Time frame: At the time of delivery.

  2. Time to Active Phase and Second Stage of Labor

    The duration (in hours) from balloon insertion to the onset of the active phase of labor, and the duration of the second stage of labor.

    Time frame: From balloon insertion up to delivery, assessed up to 48 hours after balloon insertion.

  3. Maternal Complications

    Composite rate of maternal complications including chorioamnionitis, postpartum hemorrhage (PPH, defined as estimated blood loss greater than 1000 mL), need for blood transfusion, maternal fever during or after delivery, and obstetric anal sphincter injuries (OASIS).

    Time frame: From balloon insertion up to 48 hours postpartum.

  4. Adverse Neonatal Outcomes

    Composite rate of neonatal outcomes including birthweight, Apgar scores at 1 and 5 minutes (range 0-10; higher scores indicate better neonatal condition), neonatal umbilical cord pH, rates of respiratory complications, admission to the Neonatal Intensive Care Unit (NICU), and suspected or confirmed neonatal sepsis.

    Time frame: From birth up to newborn discharge or 7 days of life.

  5. Duration of Hospitalization

    The total length of maternal hospital stay (in days) from the day of admission for labor induction to the day of postpartum discharge.

    Time frame: From admission for induction up to hospital discharge (approximately 3-5 days).

07

Study locations

1 of 1 sites recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07689357
Responsible party
Bar Rosh MD (Resident, Rambam Health Care Campus) — Principal investigator
First posted
Jul 8, 2026
Start date
May 27, 2026
Primary completion
Jun 1, 2028 (estimated)
Completion
Nov 1, 2028 (estimated)
Last update
Jul 8, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion